WAVE Life Sciences Ltd. (NASDAQ:WVE) insider Chandra Vargeese sold 1,500 shares of the stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $35.00, for a total transaction of $52,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

WAVE Life Sciences Ltd. (NASDAQ WVE) traded up $0.65 during midday trading on Friday, hitting $36.10. 120,253 shares of the stock were exchanged, compared to its average volume of 184,295. The company has a quick ratio of 11.50, a current ratio of 11.50 and a debt-to-equity ratio of 0.01. WAVE Life Sciences Ltd. has a 1-year low of $15.15 and a 1-year high of $40.15.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.03. The business had revenue of $0.68 million during the quarter, compared to analyst estimates of $0.77 million. WAVE Life Sciences had a negative net margin of 3,338.68% and a negative return on equity of 59.52%. sell-side analysts predict that WAVE Life Sciences Ltd. will post -3.76 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 Asset Management L.P. purchased a new stake in shares of WAVE Life Sciences in the third quarter worth approximately $13,679,000. Granite Point Capital Management L.P. acquired a new position in WAVE Life Sciences in the third quarter worth approximately $653,000. Schwab Charles Investment Management Inc. increased its holdings in WAVE Life Sciences by 6.2% in the third quarter. Schwab Charles Investment Management Inc. now owns 56,537 shares of the company’s stock worth $1,230,000 after buying an additional 3,325 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in WAVE Life Sciences in the third quarter worth approximately $2,634,000. Finally, Bank of New York Mellon Corp increased its holdings in WAVE Life Sciences by 5.5% in the third quarter. Bank of New York Mellon Corp now owns 49,693 shares of the company’s stock worth $1,081,000 after buying an additional 2,589 shares during the last quarter. 69.47% of the stock is owned by institutional investors and hedge funds.

Several research firms have recently weighed in on WVE. Zacks Investment Research upgraded shares of WAVE Life Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, October 12th. Leerink Swann reaffirmed an “outperform” rating and set a $53.00 price objective (up from $42.00) on shares of WAVE Life Sciences in a research note on Wednesday, November 15th. Mizuho set a $34.00 price objective on shares of WAVE Life Sciences and gave the company a “buy” rating in a research note on Saturday, October 21st. BidaskClub raised shares of WAVE Life Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, November 14th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $40.00 price objective (down from $42.00) on shares of WAVE Life Sciences in a research note on Thursday, August 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $41.60.

COPYRIGHT VIOLATION WARNING: “Chandra Vargeese Sells 1,500 Shares of WAVE Life Sciences Ltd. (WVE) Stock” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.watchlistnews.com/chandra-vargeese-sells-1500-shares-of-wave-life-sciences-ltd-wve-stock/1726001.html.

About WAVE Life Sciences

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.